Milk Thistle (80% Silymarin).

Standardised silymarin is dominated by poorly soluble flavonolignans whose absorption is the limiting step. Complexing them with phosphatidylcholine raises systemic exposure and is the established delivery form.

NAC supplies the cysteine that limits glutathione synthesis in liver cells. Standardised silymarin acts on the same glutathione economy from the sparing side.

Alpha lipoic acid regenerates glutathione, ascorbate and tocopherol after they are oxidised. It has been formulated with silymarin and selenium as a hepatic antioxidant trio for years.

Selenium is the active centre of glutathione peroxidase, which uses glutathione to reduce lipid hydroperoxides. It turns the glutathione silymarin helps preserve into working antioxidant capacity.

Cynarin from artichoke acts on bile secretion, the route fat-soluble waste leaves the liver. Silymarin works at the hepatocyte membrane and redox level, so the pairing covers both cell and outflow.

Dandelion root bitters stimulate bile production and normal digestive secretion. It is a traditional companion to silymarin on the outflow side of liver formulas.

Schisandra lignans act on hepatic phase I and phase II enzymes, overlapping the conjugation pathways silymarin influences. The combination is standard in liver blends.

Both curcumin and silymarin act on Nrf2, the transcription factor that switches on phase II conjugating enzymes. Their induction of that programme overlaps.

Betaine remethylates homocysteine to methionine and feeds the SAM-e pool used to make phosphatidylcholine. That phospholipid is what packages fat for export from liver cells.

Silymarin flavonolignans are cleared by UGT glucuronidation and piperine slows that step, raising their exposure. The same inhibition reaches other actives in the same capsule.

The phenolic hydroxyls in silymarin bind iron in the gut lumen and lower uptake from a non-heme iron salt taken alongside it. Spacing the doses avoids the competition.

Silymarin flavonolignans scavenge radicals in the aqueous phase while tocopherols act inside the lipid bilayer. The two cover different compartments of the same membrane. Combining them is standard practice in antioxidant formulas. The pairing is mechanistic; a clinical benefit of the combination over either alone has not been established here.

Ascorbate regenerates oxidised phenolic radicals back to their reduced form, which applies to flavonolignan radicals as it does to tocopheroxyl. That keeps the silymarin fraction in its active state longer in an aqueous environment. It also stabilises the extract in solution during formulation. The relationship is redox chemistry rather than a measured clinical pairing.

A recurring finding in silymarin pharmacology is preservation of cellular glutathione during oxidative challenge, mostly from cell and animal work. Supplying glutathione directly acts on the same pool from the other end. The two approaches converge on hepatic redox balance without sharing a transporter. Oral glutathione bioavailability is its own separate question.

Both silymarin and quercetin are substrates and inhibitors of UGT and sulfotransferase enzymes and of intestinal efflux transporters. Taken together, each can slow the other's phase II conjugation, which tends to raise circulating levels of both. That is a pharmacokinetic interaction, useful in formulation and worth knowing about with any co-administered substance handled by the same enzymes. The direction is reasonably predictable, the magnitude is not.

Both are polyphenols with poor oral bioavailability and heavy first-pass glucuronidation, and both engage Nrf2-linked antioxidant response signalling in preclinical work. Products aiming at hepatic antioxidant support commonly pair them. Each competes for the same conjugation capacity, so co-dosing may raise exposure to both. Evidence for the combination in people is thin.

Catechins and flavonolignans overlap in phase II metabolism and in radical scavenging capacity. Formulas targeting the same tissue frequently carry both. Because high-dose concentrated catechin extracts carry their own hepatic monitoring considerations, dosing the pair deserves attention rather than assumption. Read it as mechanistic overlap, not as a tested combination.

Sulforaphane is the canonical Nrf2 activator and drives phase II conjugating enzyme expression. Silymarin has been reported to touch the same pathway in cell and animal models. Together they act on induction and on direct scavenging respectively. The convergence is preclinical and should be read that way.

A randomised trial of a nutraceutical containing yeast beta-glucan, prebiotics, minerals and Silybum marianum reported changes in metabolic markers in adults. Because the product was a blend, the contribution of any single component cannot be separated out. The pairing has a human trial behind it as a combination, not as a demonstrated interaction. That is a real but narrow basis.

The same blended nutraceutical carried prebiotic fibre alongside silymarin, and follow-up work from the group examined microbiota shifts with related blends. Fibre fermentation and flavonolignan action are unrelated mechanisms that happen to sit in the same product. Colonic bacteria also deconjugate polyphenol glucuronides, which is a plausible but unmeasured route for fibre to change silymarin exposure. Attribution to inulin alone is not available.

Choline is required for phosphatidylcholine synthesis and therefore for packaging triglyceride into VLDL for export from the liver. Silymarin does not supply that substrate. In formulas aimed at normal hepatic lipid handling the two address different steps. This is settled nutritional biochemistry, not an interaction study.

Ubiquinol terminates lipid peroxidation chains inside the inner mitochondrial membrane, a compartment flavonolignans reach poorly. Silymarin's reported mitochondrial effects in preclinical work sit upstream of that. Both are lipophilic and benefit from being taken with fat. The combination is formulation reasoning supported by mechanism.

Silymarin is poorly water soluble and its oral bioavailability is low, which is why phospholipid complexes and micellar systems exist. Lecithin provides the phospholipid that forms those complexes and disperses the extract in the gut. The bioavailability gain is measured as a plasma concentration, a marker, not as a clinical result. Ratio and process matter more than simply having both present.

FAD derived from riboflavin is the cofactor for glutathione reductase, the enzyme that returns oxidised glutathione to its reduced form. Any strategy that relies on maintaining reduced glutathione depends on that recycling step. Riboflavin status is therefore a background requirement rather than an additive antioxidant. It is textbook enzymology.

Calcium D-glucarate inhibits beta-glucuronidase and so reduces the deconjugation that returns glucuronidated compounds to circulation. Silybin is extensively glucuronidated and undergoes enterohepatic recycling, so blocking that recycling would be expected to lower silybin exposure rather than raise it. The direction follows from the chemistry; no study measures the pair. Worth flagging because the intuition runs the other way.

Zinc together with copper forms the catalytic centre of cytosolic superoxide dismutase, the first enzymatic step in handling superoxide. Silymarin scavenges radicals non-enzymatically downstream of that. The two act at different points of the same cascade. This is established cofactor biochemistry.

Silymarin and berberine appear together in supplements aimed at normal glucose and lipid handling, and berberine has human data on those markers. Both are also handled by intestinal efflux transporters, so exposure to each may shift when they are combined. The metabolic effects reported are markers, not clinical outcomes. Combination data in people is limited.